What happened
A study published in Nature Medicine on 12 October uses two large datasets to reconstruct how laboratory markers change around menopause. The researchers describe step-like shifts across several body systems, including hormones, bone metabolism, liver and kidney tests and blood lipids. Their analysis draws on more than 300 million laboratory tests.
“Menopause is a normal and inevitable life stage”
A population pattern, not a personal forecast
The team, led by Uri Alon at the Weizmann Institute of Science, used a computational method to account for variation in the timing of the final menstrual period. Some hormonal changes appeared more than a decade beforehand. Women reporting hormone therapy had smaller shifts in several markers, an association that does not establish a treatment effect.
Why the interpretation matters
Independent expert reaction is mixed. Physiologist Mia Schaumberg highlighted the study’s scale and its attention to systems beyond reproduction. Hickey questioned the clinical significance of the changes and warned that the cliff description could alarm women. Andrew Shelling described the findings as a starting point for further investigation.
The distinction matters for how this research is communicated. A change in an average laboratory trajectory is not automatically a sudden deterioration in an individual’s health. Nor does a very large number of tests turn an observational comparison into a randomized trial. The analysis cannot resolve every difference between people who use hormone therapy and those who do not.
Why it matters
Menopause research benefits from looking beyond periods and hot flashes to how multiple systems change together. The useful question raised here is whether better tracking could improve understanding of the transition. The findings do not establish a universal countdown, a new routine blood-test panel or a reason for every woman to start hormone therapy.
What to watch
Prospective studies following the same people through menopause, independent assessment of the reconstruction method, and evidence that particular marker changes predict outcomes that matter to patients. Treatment decisions still require a separate assessment of established benefits, risks and individual circumstances.
